Scientific Industries, Inc. · OTC:SCND
Scientific Industries — Investor Presentation (September 2023)
19 slides from Scientific Industries's investor presentation, September 2023
Slide 1: Scientific Industries, Inc. Investor Presentation
Scientific Industries, Inc. (OTCQB: SCND) Digitally Simplifying Science. INVESTOR PRESENTATION September 2023 PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the federal securities laws. All statements, other than statements of historical facts, included in this presentation that address activities, events or developments that Scientific Industries, Inc. and its subsid
Slide 3: Scientific Industries Investment Highlights
Scientific Industries Investment Highlights Scientific Industries is a Life Science Tools Company comprised of two businesses; its legacy base business, characterized by stable revenues, growth, and earnings, and its SBI business, we expect to deliver outsized growth in the coming years ▪ Historic l
Slide 4: Leadership and Board Track Record of Proven Success in Life Sciences
Scientific Industries’ Leadership and Board has a Track Record of Proven Success in the Life Sciences Business. Helena Santos John Moore Reginald Averilla Daniel Gruenes SCND President & CEO SCND Chairman SCND CFO SBI President & CEO Marcus Frampton Chris Cox Dr. Juergen Schumacher John Nicols SCND
Slide 5: Profitable legacy business supporting high growth, revolutionary bioprocessing division
Profitable legacy business supporting high growth, revolutionary bioprocessing division. STABLE & PROFITABLE INVESTMENT FOR GROWTH Founded in 1954 Acquired in 2014 Acquisition in 2021 The World Enabling Digitally Enabling the Synthetic Biology Leader in Simplified Pharmacy with Revolution via Digita
Slide 6: Profitable & Proven Base Business
Profitable & Proven Base Business Torbal is a 100+ year franchise, with a dominant installed base in pharmacy balances and a huge growth opportunity due to federal track and trace rules that take effect in Nov 2023. Genie + Torbal Revenue(4) Mixers and shakers, rotators/rockers, refrigerated and sha
Slide 7: Positioned to achieve significant operating leverage
Scientific Industries is positioned to achieve significant operating leverage driven by the strong growth potential of its bioprocessing operations. ▪ Over the longer-term, we believe Scientific Industries has the potential to achieve 70% gross $180M margins and 50% EBITDA margins, driven mainly by
Slide 8: SBI addresses a $2B Market in Synthetic Biology with DOTS Technology
SBI addresses a $2B Market(1) in Synthetic Biology with its DOTS Technology platform for Digitally Simplified Bioprocessing. Digitally Simplified Bioprocessing. Daniel Grünes President & CEO of SBI PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED 8
Slide 9: The iPhone transformed an entire industry by merging technologies
SBI addresses In 2007, a $2B the iPhone Market(1)an transformed in entire Synthetic Biology industry by bringing by merging various capabilities of technologies established into solutions a single, small, to the affordable andmost ubiquitous easy-to-use vessel. device. Simplicity Sensing Size Knowle
Slide 10: It's been done before: the iPhone in 2007
It’s2007, In beenthe done iPhone before: transformed in 2007, theaniPhone entire transformed industry by merging it’s fieldvarious by merging technologiestechnologies established into a single,into small, a small, affordable affordable and easy-to-use and easy-to-use device. device. Simplicity Sensi
Slide 11: Bioprocess development costs $3 Million and takes around 3 Years
Due to the lack of affordable and easy-to-use technologies, the average bioprocess development costs $3 Million and takes around 3 Years(2). Engineered 14 Million Cells Shake Flasks in the US alone(6) Bioprocess + Cheap Antibodies, Enzymes, Biofuels, Bioplastics, Raw Material Bulk Chemicals, … Well
Slide 12: DOTS Technology enables fermenter-like experiments in shake flasks
SBI’s DOTS Technology enables Fermenter-like experiments in shake flasks and helps customers to bring down costs and development times. Engineered 14 Million Cells Shake Flasks in the US alone(6) Bioprocess + Cheap Antibodies, Enzymes, Biofuels, Bioplastics, Raw Material Bulk Chemicals, … Well Plate
Slide 13: The DOTS Technology Platform consists of components
The DOTS Technology Platform consists of 4 components and a first full version will be available to the market in the beginning of 2024. Shake Flask Simple Cultivation Vessel % DOTS Software Real-Time Data Insights, Analysis & Visualization Feeding System Feedback-controlled, Automated Addition of L
Slide 14: Investments into DOTS components pay off within a year
Case study shows that investments into DOTS components pay off within a year, due to significant savings in materials and labor hours. Bond Pet Foods DOTS Biomass Labor Costs Saved Material Costs Saved Case Study(8) $ 54,942 $ 28,860 $ 43,680 Investment per year per year Investment in DOTS Biomass p
Slide 15: We have all Puzzle Pieces in Hand to Unlock the Market
We have all Puzzle Pieces in Hand to Unlock the Market of Digitally Simplified Bioprocessing – Shaping the Future of Biotechnology. 50 Team Members >350 Customers with 20 R&D + 18 Marketing & Sales in >25 Countries around the Globe >8 Years Spent in R&D >20 Distributors to Develop and Approve Core T
Slide 16: Historical Financial Performance
Historical Financial Performance Benchtop laboratory equipment revenues Legacy bioprocessing systems royalty revenues COMMENTARY Bioprocessing revenues ▪ Top line growth with resiliency $12 ,0 00 Gross Margin 65 % $9, 00 0 $10,797 $10,880 65 % to global instability supported USD in 000’s by Genie pr
Slide 17: Capitalization Snapshot
Capitalization Snapshot As of June 30, 2023 As of September 20, 2023 Balance Sheet Shares Outstanding 7,003,599 Debt $0 Options 1,085,097 WAEP $8.46 Cash & Cash Equivalents(12) $2,488,600 Warrants 3,422,510 WAEP $8.98 PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED 17
Slide 18: Thank You
Thank You Get in Contact: John Moore: [email protected] Helena Santos: [email protected] Daniel Grünes: [email protected] Reginald Averilla: [email protected] INVESTOR PRESENTATION September 2023 PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED PRI
Slide 19: References
References (1) Market size was estimated based on two market reports describing the global Small-Scale Bioreactor Market: a) “Small-Scale Bioreactors Market 2023-2030”, Grand View Research, 2022, Report ID GVR-4-68040-046-5, https://www.grandviewresearch.com/industry-analysis/small-scale-bioreactors
Scientific Industries — Investor Presentation (September 2023) on 6ix